Decanoic Acid

Decanoic Acid

SCHEMBL2783383

CCCCCCCC(=O)OCCC(C)C.CCCCCCCCCC(=O)O

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGKA P23743 1/20 0.62
PAM P19021 2/20 0.57
GPR84 Q9NQS5 7/20 0.55
PPARG P37231 7/20 0.55
PPARD Q03181 7/20 0.55
PPARA Q07869 7/20 0.55
HDAC11 Q96DB2 5/20 0.55
TSHR P16473 4/20 0.55
PTPN1 P18031 3/20 0.55
ALDH1A1 P00352 2/20 0.55
TLR2 O60603 2/20 0.55
TDP1 Q9NUW8 2/20 0.55
FABP4 P15090 2/20 0.55
FFAR1 O14842 2/20 0.55
FFAR4 Q5NUL3 2/20 0.55
SLC22A6 Q4U2R8 1/20 0.55
SLC22A8 Q8TCC7 1/20 0.55
MEN1 O00255 1/20 0.55
ESR1 P03372 1/20 0.55
ALOX15 P16050 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Octanoic Acid SCHEMBL31096997 1.00 DGKA (0.62) DGKAPAMGPR84PPARGPPARD
Stearic Acid SCHEMBL27719642 0.94 MAPT (0.56) DGKAPAMGPR84PPARGPPARD
SCHEMBL27842955 0.93 DGKA (0.50) DGKAPAMGPR84PPARGPPARD
SCHEMBL2032699 0.93 DGKA (0.71) DGKAPAMTSHRALDH1A1MEN1
SCHEMBL19409845 0.93 DGKA (0.71) DGKAPAMTSHRALDH1A1MEN1
SCHEMBL23141646 0.93 DGKA (0.71) DGKAPAMTSHRALDH1A1MEN1
SCHEMBL120186 0.93 DGKA (0.71) DGKAPAMTSHRALDH1A1MEN1
SCHEMBL2397395 0.93 DGKA (0.71) DGKAPAMTSHRALDH1A1MEN1
SCHEMBL856632 0.93 DGKA (0.71) DGKAPAMTSHRALDH1A1MEN1
SCHEMBL37144 0.93 DGKA (0.71) DGKAPAMTSHRALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680186-A1 SUNSCREEN COMPOSITION DSM IP Assets B.V. (NL) 2026-01-21 EP claimed
EP-4680185-A1 SKIN CARE COMPOSITION DSM IP Assets B.V. (NL) 2026-01-21 EP claimed
WO-2024189014-A1 SKIN CARE COMPOSITION DSM IP ASSETS B.V. (NL) 2024-09-19 WO claimed
WO-2024189016-A1 SUNSCREEN COMPOSITION DSM IP ASSETS B.V. (NL) 2024-09-19 WO claimed
EP-2208768-B1 A bituminous cold glue IMPERBEL N V SA (BE) 2013-03-27 EP claimed
US-8257483-B2 Bituminous cold glue S.A. IMPERBEL N.V. (BE) 2012-09-04 US claimed
US-20100212546-A1 Bituminous cold glue S.A. IMPERBEL N.V. (BE) 2010-08-26 US claimed
EP-2208768-A1 A bituminous cold glue S.A. Imperbel N.V. (BE) 2010-07-21 EP claimed
US-20260083652-A1 RENEWABLE ESTER EMOLLIENT FOR ENHANCED CUTANEOUS PERMEATION OXITENO S.A. INDÚSTRIA E COMÉRCIO (BR) 2026-03-26 US disclosed
EP-4680186-A1 SUNSCREEN COMPOSITION DSM IP Assets B.V. (NL) 2026-01-21 EP disclosed
EP-4680185-A1 SKIN CARE COMPOSITION DSM IP Assets B.V. (NL) 2026-01-21 EP disclosed
EP-4680185-A1 SKIN CARE COMPOSITION DSM IP Assets B.V. (NL) 2026-01-21 EP disclosed
EP-4680186-A1 SUNSCREEN COMPOSITION DSM IP Assets B.V. (NL) 2026-01-21 EP disclosed
WO-2026002977-A1 SUNSCREEN COMPOSITION DSM IP ASSETS B.V. (NL) 2026-01-02 WO disclosed
WO-2024189014-A1 SKIN CARE COMPOSITION DSM IP ASSETS B.V. (NL) 2024-09-19 WO disclosed
WO-2024189014-A1 SKIN CARE COMPOSITION DSM IP ASSETS B.V. (NL) 2024-09-19 WO disclosed
EP-2208768-B1 A bituminous cold glue IMPERBEL N V SA (BE) 2013-03-27 EP disclosed
US-8257483-B2 Bituminous cold glue S.A. IMPERBEL N.V. (BE) 2012-09-04 US disclosed
US-20100212546-A1 Bituminous cold glue S.A. IMPERBEL N.V. (BE) 2010-08-26 US disclosed
EP-2208768-A1 A bituminous cold glue S.A. Imperbel N.V. (BE) 2010-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260083652-A1 RENEWABLE ESTER EMOLLIENT FOR ENHANCED CUTANEOUS PERMEATION ELOVL3, CRAT, ELOVL5 DGKA 2073/4885PAM 4565/4885GPR84 806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.